

# ASX Announcement

Medibio Limited – 11 March 2022



## Medibio Announces Entitlement Offer Result

**Melbourne, Australia and Minneapolis, MN – 11 March 2022: Medibio Limited (MEB or the Company)** (ASX: MEB) (OTCPINK: MDBIF), a health technology company is pleased to advise the results of the Non-Renounceable Entitlement Offer ("**Entitlement Offer**") announced by the Company on Wednesday, 15 December 2021 which closed on Friday, 4 March 2022.

The Company received applications for 145,889,750 new fully paid ordinary shares amounting to total subscriptions of \$729,448.75. The Company and CPS will work together on a best endeavors to place any shortfall of the Entitlement Offer in the three month period after the close of the Entitlement Offer.

Below is a table outlining the effects of the Entitlement Offer on the capital structure of the Company:

EVENT	NO. OF SHARES
Shares currently on issue	2,251,100,373
Maximum shares offered under the Entitlement Issue	687,018,117
Shares applied for under the Entitlement Offer	110,106,151
Additional shares applied for under the Entitlement Offer	35,783,599
<b>Shortfall shares</b>	<b>541,128,367</b>

As part of the Entitlement Offer the Company also has issued 72,944,876 MEBOC quoted options on the basis for 1 option for every 2 shares subscribed for under the Entitlement Offer. The number of shares on issue in the Company after the issue of entitlement shares will be 2,396,990,123.

The Board would like to thank all shareholders for their continued support of the Company.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

### For Further information:

Mathew Watkins  
Company Secretary  
T: +61 3 9692 7222

### About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).